Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Fachpsychotherapie Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Skeletal Radiology
Erschienen in:

25.09.2021 | Review Article

Malignant giant cell tumour of bone: a review of clinical, pathological and imaging features

verfasst von: Ismail Tahir, Vanghelita Andrei, Robin Pollock, Asif Saifuddin

Erschienen in: Skeletal Radiology | Ausgabe 5/2022

Einloggen, um Zugang zu erhalten

Abstract

Giant cell tu mour accounts for up to 5% of all bone tumours and malignant giant cell tumour arises in < 10% of cases, representing sarcomatous transformation. Primary malignant giant cell tumour of bone occurs when sarcomatous tissue is observed within conventional giant cell tumour histologically on initial presentation. Secondary malignant giant cell tumour of bone occurs in a region of previously treated giant cell tumour, with most cases arising due to prior radiotherapy. Malignancy in giant cell tumour of bone does not have any unique clinical or imaging features compared to conventional aggressive disease. Historically, malignant giant cell tumour of bone has a poor prognosis which is worse in cases of secondary malignancy. This article aims to present the clinical, pathological and imaging features of MGCTB based on a review of the literature and illustrated by examples from our experience.
Literatur
1.
Futamura N, Urakawa H, Tsukushi S, Arai E, Kozawa E, Ishiguro N, et al. Giant cell tumor of bone arising in long bones possibly originates from the metaphyseal region. Oncol Lett. 2016;11(4):2629–34.PubMedPubMedCentralCrossRef
2.
Flanagan A. M. YA, O’Donnell PG, Larousserie F (2020) Giant cell tumour of bone. WHO Classification of Tumours Editorial Board. Soft tissue and bone tumours (WHO Classification of Tumours 5th ed.; vol.3). International Agency for Research on Cancer, Lyon, pp440–446
3.
Damron T. Dahlin’s bone tumors: general aspects and data on 10,165 cases. JBJS. 2010;92(12):2261.
4.
Turcotte RE. Giant cell tumor of bone. Orthop Clin N Am. 2006;37(1):35–51.CrossRef
5.
Errani C, Ruggieri P, Asenzio MA, Toscano A, Colangeli S, Rimondi E, et al. Giant cell tumor of the extremity: a review of 349 cases from a single institution. Cancer Treat Rev. 2010;36(1):1–7.PubMedCrossRef
6.
Dhillon MS, Prasad P. Multicentric giant cell tumour of bone. Acta Orthop Belg. 2007;73(3):289.PubMed
7.
Mavrogenis AF, Igoumenou VG, Megaloikonomos PD, Panagopoulos GN, Papagelopoulos PJ, Soucacos PN. Giant cell tumor of bone revisited. SICOT J. 2017;3:54–54.PubMedPubMedCentralCrossRef
8.
Rendina D, De Filippo G, Ralston SH, Merlotti D, Gianfrancesco F, Esposito T, et al. Clinical characteristics and evolution of giant cell tumor occurring in Paget’s disease of bone. J Bone Miner Res. 2015;30(2):257–63.PubMedCrossRef
9.
Tanaka H, Yasui N, Kuriskaki E, Shimomura Y. The Goltz syndrome associated with giant cell tumour of bone. Int Orthop. 1990;14(2):179–81.PubMedCrossRef
10.
Palmerini E, Picci P, Reichardt P, Downey G. Malignancy in giant cell tumor of bone: a review of the literature. Technol Cancer Res Treat. 2019;18:1533033819840000.PubMedCrossRef
11.
Hutter RV, Worcester JN Jr, Francis KC, Foote FW Jr, Stewart FW (1962) Benign and malignant giant cell tumors of bone. A clinicopathological analysis of the natural history of the disease. Cancer 15(4):653–690
12.
Dahlin DC, Cupps RE, Johnson EW Jr. Giant-cell tumor: a study of 195 cases. Cancer. 1970;25(5):1061–70.PubMedCrossRef
13.
14.
Bertoni F, Bacchini P, Staals EL. Malignancy in giant cell tumor of bone. Cancer Interdiscip Int J Am Cancer Soc. 2003;97(10):2520–9.
15.
Gong L, Liu W, Sun X, Sajdik C, Tian X, Niu X, et al. Histological and clinical characteristics of malignant giant cell tumor of bone. Virchows Arch. 2012;460(3):327–34.PubMedCrossRef
16.
Liu W, Chan CM, Gong L, Bui MM, Han G, Letson GD, et al. Malignancy in giant cell tumor of bone in the extremities. J Bone Oncol. 2021;26:100334.PubMedCrossRef
17.
Nascimento AG, Huvos AG, Marcove RC. Primary malignant giant cell tumor of bone. A study of eight cases and review of the literature. Cancer. 1979;44(4):1393–402.PubMedCrossRef
18.
Domovitov SV, Healey JH. Primary malignant giant-cell tumor of bone has high survival rate. Ann Surg Oncol. 2010;17(3):694–701.PubMedCrossRef
19.
Sanerkin N. Malignancy, aggressiveness, and recurrence in giant cell tumor of bone. Cancer. 1980;46(7):1641–9.PubMedCrossRef
20.
Rock MG, Sim F, Unni K, Witrak GA, Frassica F, Schray M, et al. Secondary malignant giant-cell tumor of bone. Clinicopathological assessment of nineteen patients. J Bone Joint Surg Am Vol. 1986;68(7):1073–9.CrossRef
21.
Mondal A, Kundu B, Gupta S, Biswas J. Secondary malignant giant cell tumour of bone–a study of five cases with short review of literature. Indian J Pathol Microbiol. 2002;45(3):273–5.PubMed
22.
Brien EW, Mirra JM, Kessler S, Suen M, Ho JKS, Yang WT. Benign giant cell tumor of bone with osteosarcomatous transformation (”dedifferentiated” primary malignant GCT): report of two cases. Skelet Radiol. 1997;26(4):246–55.CrossRef
23.
Meis JM, Dorfman HD, Nathanson SD, Haggar AM, Wu KK. Primary malignant giant cell tumor of bone: “dedifferentiated” giant cell tumor. Mod Pathol. 1989;2(5):541–6.PubMed
24.
Jaffe H, Lichtenstein L, Portis R. Giant cell tumor of bone Ist pathological appearance, grinding, supposed variants and treatment. Arch Pathol. 1940;30:993–1031.
25.
Campanacci M, Baldini N, Boriani S, Sudanese A. Giant-cell tumor of bone. JBJS. 1987;69(1):106–14.CrossRef
26.
Van Langevelde K, McCarthy CL. Radiological findings of denosumab treatment for giant cell tumours of bone. Skelet Radiol. 2020;49(9):1345–58.CrossRef
27.
Murphey MD, Nomikos GC, Flemming DJ, Gannon FH, Temple HT, Kransdorf MJ. Imaging of giant cell tumor and giant cell reparative granuloma of bone: radiologic-pathologic correlation. Radiographics. 2001;21(5):1283–309.CrossRef
28.
van der Heijden L, Dijkstra PS, Campanacci DA, Gibbons CMH, van de Sande MA. Giant cell tumor with pathologic fracture: should we curette or resect? Clin Orthop Relat Res. 2013;471(3):820–9.PubMedCrossRef
29.
Picci P, Sieberova G, Alberghini M, Balladelli A, Vanel D, Hogendoorn PC, et al. Late sarcoma development after curettage and bone grafting of benign bone tumors. Eur J Radiol. 2011;77(1):19–25.PubMedCrossRef
30.
Presneau N, Baumhoer D, Behjati S, Pillay N, Tarpey P, Campbell PJ, et al. Diagnostic value of H3F3A mutations in giant cell tumour of bone compared to osteoclast-rich mimics. J Pathol Clin Res. 2015;1(2):113–23.PubMedPubMedCentralCrossRef
31.
Amary F, Berisha F, Ye H, Gupta M, Gutteridge A, Baumhoer D, et al. H3F3A (Histone 3.3) G34W immunohistochemistry: a reliable marker defining benign and malignant giant cell tumor of bone. Am J Surg Pathol. 2017;41(8):1059–68.PubMedPubMedCentralCrossRef
32.
Girolami I, Mancini I, Simoni A, Baldi GG, Simi L, Campanacci D, et al. Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series. J Clin Pathol. 2016;69(3):240–7.PubMedCrossRef
33.
Yamamoto H, Iwasaki T, Yamada Y, Matsumoto Y, Otsuka H, Yoshimoto M, et al. Diagnostic utility of histone H3. 3 G34W, G34R, and G34V mutant-specific antibodies for giant cell tumors of bone. Hum Pathol. 2018;73:41–50.PubMedCrossRef
34.
Luengo-Alonso G, Mellado-Romero M, Shemesh S, Ramos-Pascua L, Pretell-Mazzini J. Denosumab treatment for giant-cell tumor of bone: a systematic review of the literature. Arch Orthop Trauma Surg. 2019;139(10):1339–49.PubMedCrossRef
35.
Mintz GA, Abrams AM, Carlsen GD, Melrose RJ, Fister HW. Primary malignant giant cell tumor of the mandible: report of a case and review of the literature. Oral Surg Oral Med Oral Pathol. 1981;51(2):164–71.PubMedCrossRef
36.
Aoki J, Tanikawa H, Ishii K, Seo G, Karakida O, Sone S, et al. MR findings indicative of hemosiderin in giant-cell tumor of bone: frequency, cause, and diagnostic significance. AJR Am J Roentgenol. 1996;166(1):145–8.PubMedCrossRef
37.
O’Reilly M, Chew FS. The scintigraphic features of giant-cell tumors in relation to other imaging modalities. Clin Nucl Med. 1996;21(1):43–8.PubMedCrossRef
38.
Muheremu A, Ma Y, Huang Z, Shan H, Li Y, Niu X. Diagnosing giant cell tumor of the bone using positron emission tomography/computed tomography: a retrospective study of 20 patients from a single center. Oncol Lett. 2017;14(2):1985–8.PubMedPubMedCentralCrossRef
39.
Mori Y, Tsuchiya H, Karita M, Nonomura A, Nojima T, Tomita K. Malignant transformation of a giant cell tumor 25 years after initial treatment. Clin Orthop Relat Res. 2000;381:185–91.CrossRef
40.
Takesako H, Osaka E, Yoshida Y, Sugitani M, Tokuhashi Y. Secondary malignant giant cell tumor of bone due to malignant transformation 40 years after surgery without radiation therapy, presenting as fever of unknown origin: a case report. J Med Case Reports. 2016;10:47–47.CrossRef
41.
Kriz J, Eich HT, Muecke R, Buentzel J, Mueller R-P, Bruns F, et al. Radiotherapy for giant cell tumors of the bone: a safe and effective treatment modality. Anticancer Res. 2012;32(5):2069–73.PubMed
42.
Skubitz KM. Giant cell tumor of bone: current treatment options. Curr Treat Options Oncol. 2014;15(3):507–18.PubMedCrossRef
43.
Wojcik J, Rosenberg AE, Bredella MA, Choy E, Hornicek FJ, Nielsen GP, et al. Denosumab-treated giant cell tumor of bone exhibits morphologic overlap with malignant giant cell tumor of bone. Am J Surg Pathol. 2016;40(1):72–80.PubMedCrossRef
44.
Tsukamoto S, Righi A, Vanel D, Honoki K, Donati DM, Errani C. Development of high-grade osteosarcoma in a patient with recurrent giant cell tumor of the ischium while receiving treatment with denosumab. Jpn J Clin Oncol. 2017;47(11):1090–6.PubMedCrossRef
45.
Broehm CJ, Garbrecht EL, Wood J, Bocklage T. Two cases of sarcoma arising in giant cell tumor of bone treated with denosumab. Case Rep Med. 2015;2015:767198.PubMedPubMedCentralCrossRef
46.
Park A, Cipriano CA, Hill K, Kyriakos M, McDonald DJ. Malignant transformation of a giant cell tumor of bone treated with denosumab: a case report. JBJS Case Connect. 2016;6(3):e78.PubMedCrossRef
47.
Aponte-Tinao LA, Piuzzi NS, Roitman P, Farfalli GL. A high-grade sarcoma arising in a patient with recurrent benign giant cell tumor of the proximal tibia while receiving treatment with denosumab. Clin Orthop Relat Res. 2015;473(9):3050–5.PubMedPubMedCentralCrossRef
48.
Li J, Zhu Y, Wei Y. Fibrosarcoma development 15 years after curettage and bone grafting of giant cell tumor of bone. Orthopedics. 2014;37(5):e512-516.PubMedCrossRef
49.
Chen L, Ding XY, Wang CS, Si MJ, Du LJ, Lu Y. Triple-phase dynamic MRI: a new clue to predict malignant transformation of giant cell tumor of bone. Eur J Radiol. 2014;83(2):354–9.PubMedCrossRef
50.
Gerrand C, Athanasou N, Brennan B, Grimer R, Judson I, Morland B, et al. UK guidelines for the management of bone sarcomas. Clinical Sarcoma Res. 2016;6(1):7.PubMedPubMedCentralCrossRef
51.
Andritsch E, Beishon M, Bielack S, Bonvalot S, Casali P, Crul M, et al. ECCO essential requirements for quality cancer care: soft tissue sarcoma in adults and bone sarcoma. A critical review. Crit Rev Oncol Hematol. 2017;110:94–105.PubMedCrossRef
52.
Saifuddin A, Sharif B, Oliveira I, Kalus S, Barnett J, Pressney I. The incidence of skip metastases on whole bone MRI in high-grade bone sarcomas. Skelet Radiol. 2020;49(6):945–54.CrossRef
53.
Yang Y, Huang Z, Niu X, Xu H, Li Y, Liu W. Clinical characteristics and risk factors analysis of lung metastasis from benign giant cell tumor of bone. J Bone Oncol. 2017;7:23–8.PubMedPubMedCentralCrossRef
54.
Beebe-Dimmer JL, Cetin K, Fryzek JP, Schuetze SM, Schwartz K. The epidemiology of malignant giant cell tumors of bone: an analysis of data from the Surveillance, Epidemiology and End Results Program (1975–2004). Rare Tumors. 2009;1(2):e52–e52.PubMedPubMedCentralCrossRef
55.
Lin J-L, Wu Y-H, Shi Y-F, Lin H, Nisar M, Meftah Z, et al. Survival and prognosis in malignant giant cell tumor of bone: a population-based analysis from 1984 to 2013. J Bone Oncol. 2019;19:100260.PubMedPubMedCentralCrossRef
Metadaten
Titel
Malignant giant cell tumour of bone: a review of clinical, pathological and imaging features
verfasst von
Ismail Tahir
Vanghelita Andrei
Robin Pollock
Asif Saifuddin
Publikationsdatum
25.09.2021
Verlag
Springer Berlin Heidelberg
Erschienen in
Skeletal Radiology / Ausgabe 5/2022
Print ISSN: 0364-2348
Elektronische ISSN: 1432-2161
DOI
https://doi.org/10.1007/s00256-021-03913-6

Weitere Artikel der Ausgabe 5/2022

The radiological findings in complex elbow fracture-dislocation injuries

  • Review Article

Percutaneous CT-guided corticosteroid injection for the treatment of osseous Langerhans cell histocytosis: a three institution retrospective analysis

  • Scientific Article

Update on imaging of the discoid meniscus

  • Review Article

Test yourself: Recurrent right groin lump

  • Test Yourself: Answer

Test yourself: recurrent right groin lump

  • Test Yourself: Question

The posterior oblique ligament in MRI of acute knee trauma

  • Scientific Article

Neu im Fachgebiet Radiologie

Hölzerner Fremdkörper in der Orbita? Zuerst eine CT!

Besteht der Verdacht, dass ein Fremdkörper aus Holz in den Orbitalraum eingedrungen ist, spielt die Bildgebung eine entscheidende diagnostische Rolle. Was von CT und MRT zu erwarten ist, hat ein chinesisches Radiologenteam untersucht.

Diagnostik von Rippenfrakturen: KI schlägt Radiologen

Mensch gegen Maschine: Beim Erkennen von Rippenfrakturen in Röntgen- und CT-Aufnahmen entschied sich dieses Duell zugunsten der künstlichen Intelligenz (KI). Die Algorithmen zeigten eine höhere Sensitivität als ihre menschlichen Kollegen.

Ärztinnen überholen Ärzte bei Praxisgründungen

Bei Praxisgründungen haben inzwischen die Frauen deutlich die Nase vorn: Seit zehn Jahren wagen laut apoBank mehr Ärztinnen als Ärzte den Schritt in die Selbstständigkeit. In puncto Finanzierung sind sie aber vorsichtiger als die männlichen Kollegen.

Ambulante Behandlung darf länger dauern als stationäre

Ambulante Behandlungen haben Vorrang vor stationären - auch wenn diese läner dauern. Das hat das Bundessozialgericht klargestellt. Konkret ging es um Liposuktionen der Ober- und Unterschenkel.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise